@article{TLCR23599,
author = {Nagio Takigawa and Nobuaki Ochi and Hiromichi Yamane},
title = {Histology versus cytology: PD-L1 testing in non-small cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 3},
year = {2018},
keywords = {},
abstract = {Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab have been developed to treat malignant tumors, including non-small cell lung cancer (NSCLC). ICIs inhibit programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling between tumor cells expressing PD-L1 and cytotoxic T lymphocytes expressing PD-1.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/23599}
}